Wednesday, May 9, 2012

More Revlimid Info


Studies found lenalidomide lengthened time disease did not worsen, but risk of second cancers was doubled

WEDNESDAY, May 9 (HealthDay News) -- Three new studies confirm that the drug lenalidomide can significantly lengthen the time that people with multiple myeloma experience no worsening of their disease, either after having a stem cell transplant or getting chemotherapy.
                                   -SNIP-
The most significant and concerning side effect was an increased risk of a second cancer. In all three studies, the rate of second cancers was more than doubled in people taking lenalidomide. Low white blood cell counts were also more commonly associated with lenalidomide therapy.

No comments: